On February 1, the latest data in the United Kingdom, through the full coverage of vaccine + Pfizer oral medicine, the hospitalization rate of Omikron has dropped to almost the same as the flu. There are currently 2,827,895 confirmed cases.
January 27, a new study published in the United Kingdom on Wednesday found that more than two-thirds of the 3582 infected people who have participated in the study so far in January this year are cases that have been infected with the new crown before, which poses a new challenge to the vaccination strategy of the fourth dose of the vaccine.
An important logical order is that the first decision to use the means of detection ➕ of special drugs will there be a relaxation of control and control, and only then will there be policy ➕ public opinion guidance (various fancy reduction propaganda involving various data). Only when the coverage rate of specific drugs in regional, domestic and global test boxes ➕ reaches at least 50%, all kinds of real data will really go down the channel. Unless, of course, a new mutant virus appears to defeat Omeikoron across the board, as Omikeron defeated Delta last November. The current variant, BA2, the Sister of Amiqueron, is not a new virus and is not enough to prove that it can defeat Omikeron.
Here are some thoughts:
1. Through comprehensive coverage of "objects", including "Pfizer oral"?
2. If so, what does it mean to cover oral medicines through comprehensive coverage?
3. Will the demand for Pfizer oral drugs reduce expectations?
